ETF Holdings Breakdown of KALV

Stock Name	Kalvista Pharmaceuticals Inc
Ticker	KALV(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US4834971032
LEI	529900Q7IDA3WUGRZA51

KALV institutional holdings

The adjusted close for KALV on 2025-11-12 was 13.34

The following institutional investment holdings of KALV have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-11-12 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 31,630 USD 421,944 13.34

2025-11-12 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 31,630 0.3% USD 421,944 14.2% 13.34

Total = 63,260 USD 843,888
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	31,630	USD 421,944	13.34
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	31,630 0.3%	USD 421,944 14.2%	13.34
Total =	63,260	USD 843,888

News associated with KALV

Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Price Target at $26.43: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year […] - 2025-09-16 02:32:43
Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Target Price at $26.29: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) has received an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective […] - 2025-08-22 02:58:49
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Bank of New York Mellon Corp: Bank of New York Mellon Corp boosted its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 5.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,530 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-08-01 04:26:58
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 5.5% After Analyst Upgrade: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was up 5.5% during mid-day trading on Wednesday after JMP Securities raised their price target on the stock from $19.00 to $27.00. JMP Securities currently has a market outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.64 and last traded at $15.77. Approximately 354,539 […] - 2025-07-10 02:19:15
KalVista Pharmaceuticals (NASDAQ:KALV) Sets New 52-Week High on Analyst Upgrade: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday after Leerink Partners raised their price target on the stock from $18.00 to $20.00. Leerink Partners currently has an outperform rating on the stock. KalVista Pharmaceuticals traded as high as $15.91 and last traded at […] - 2025-07-08 03:06:43
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Price Target from Analysts: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have been given an average recommendation of “Buy” by the eight research firms that are presently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average […] - 2025-07-03 02:21:03
53,382 Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Bought by Ameriprise Financial Inc.: Ameriprise Financial Inc. acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) during the 4th quarter, HoldingsChannel reports. The fund acquired 53,382 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Several other institutional investors also recently modified their holdings of the business. SG Americas Securities LLC grew its stake […] - 2025-06-05 04:22:54
ProShare Advisors LLC Purchases Shares of 11,906 KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): ProShare Advisors LLC purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 11,906 shares of the specialty pharmaceutical company’s stock, valued at approximately $101,000. Other hedge funds and other institutional investors also recently […] - 2025-06-04 04:54:43
Graham Capital Management L.P. Buys New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Graham Capital Management L.P. bought a new stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 10,479 shares of the specialty pharmaceutical company’s stock, valued at approximately $89,000. Several other large investors have also recently bought […] - 2025-05-20 05:10:56
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $24.83 Average Target Price from Analysts: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have received a consensus recommendation of “Buy” from the eight brokerages that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price […] - 2025-05-14 02:18:47
KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) Critical Review: Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Profitability This table compares Verrica Pharmaceuticals and […] - 2025-05-13 03:14:46
Dimensional Fund Advisors LP Has $5.90 Million Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Dimensional Fund Advisors LP grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 14.7% in the 4th quarter, Holdings Channel reports. The firm owned 696,037 shares of the specialty pharmaceutical company’s stock after acquiring an additional 89,001 shares during the quarter. Dimensional Fund Advisors LP’s holdings in KalVista Pharmaceuticals were […] - 2025-05-12 04:47:02
Legal & General Group Plc Acquires 1,494 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Legal & General Group Plc boosted its stake in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 22.5% in the fourth quarter, Holdings Channel reports. The firm owned 8,144 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,494 shares during the period. Legal & General Group Plc’s holdings in KalVista […] - 2025-05-02 04:40:58
Marshall Wace LLP Purchases 103,072 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Marshall Wace LLP boosted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 691.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 117,978 shares of the specialty pharmaceutical company’s stock after acquiring an additional 103,072 shares during the period. […] - 2025-05-01 04:52:57
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Corebridge Financial Inc.: Corebridge Financial Inc. trimmed its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 17.9% during the fourth quarter, HoldingsChannel reports. The fund owned 16,945 shares of the specialty pharmaceutical company’s stock after selling 3,682 shares during the quarter. Corebridge Financial Inc.’s holdings in KalVista Pharmaceuticals were worth $144,000 as of its […] - 2025-04-15 05:06:51
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Up 8.3% – Should You Buy?: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) rose 8.3% on Monday . The stock traded as high as $11.74 and last traded at $11.60. Approximately 531,267 shares traded hands during mid-day trading, an increase of 35% from the average daily volume of 392,121 shares. The stock had previously closed at $10.71. Analyst […] - 2025-04-08 04:36:53
Intech Investment Management LLC Raises Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): Intech Investment Management LLC lifted its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 58.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,204 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,349 shares during the quarter. Intech […] - 2025-03-28 06:30:47
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from the eight analysts that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 […] - 2025-03-27 04:55:16
AlphaQuest LLC Acquires 2,588 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): AlphaQuest LLC lifted its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 17.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 17,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,588 shares during the quarter. AlphaQuest LLC’s holdings in KalVista Pharmaceuticals were worth $150,000 at the end of […] - 2025-03-18 06:03:37
HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV): HC Wainwright reissued their buy rating on shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $20.00 price objective on the specialty pharmaceutical company’s stock. Several other equities research analysts have also weighed in on KALV. Bank of America began coverage on shares […] - 2025-03-17 04:12:56
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Sees Significant Drop in Short Interest: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) was the target of a significant decrease in short interest during the month of January. As of January 31st, there was short interest totalling 7,130,000 shares, a decrease of 6.1% from the January 15th total of 7,590,000 shares. Based on an average daily volume of 368,500 shares, […] - 2025-02-19 06:42:41
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Bought by SG Americas Securities LLC: SG Americas Securities LLC grew its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 10.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,508 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,319 shares […] - 2025-02-12 06:14:54
China Universal Asset Management Co. Ltd. Grows Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV): China Universal Asset Management Co. Ltd. increased its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 24.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,329 shares of the specialty pharmaceutical company’s stock after buying an additional 2,043 shares […] - 2025-02-04 07:14:58
KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded at Citizens Jmp: Citizens Jmp upgraded shares of KalVista Pharmaceuticals (NASDAQ:KALV – Free Report) to a strong-buy rating in a report released on Friday,Zacks.com reports. KALV has been the subject of several other reports. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research note on Friday. They issued an “outperform” rating and a $19.00 target […] - 2025-02-03 04:48:44
Analysts Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Price Target at $25.00: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have received a consensus rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month […] - 2025-02-03 04:08:51
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Cross Above 50-Day Moving Average – Time to Sell?: Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $8.87 and traded as high as $8.93. KalVista Pharmaceuticals shares last traded at $8.77, with a volume of 212,998 shares. Wall Street Analysts Forecast Growth Several […] - 2025-01-30 06:51:14

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.